To evaluate the ITPRIPL1 expression level in different carcinomas, we first collected patient samples of carcinomas of the thyroid gland, esophagus, breast, lung, pancreatic duct, colon, rectum, urinary system, reproductive system, and glioma, each carcinoma type represented by at least 50 samples, and performed immunohistochemistry (IHC) with our humanized antibody (submitted). Here, ITPRIPL1 is linked to carcinoma.